Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.68 |
| ▸ | CNR2 | P34972 | 7/20 | 0.63 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764490 | 0.89 | CNR1 (0.70) | CNR1CNR2ACHE | |
| SCHEMBL6335075 | 0.89 | CNR1 (0.66) | CNR1CNR2ACHE | |
| SCHEMBL28779646 | 0.88 | CNR1 (0.68) | CNR1CNR2ACHE | |
| SCHEMBL763034 | 0.87 | CNR1 (0.64) | CNR1CNR2ACHE | |
| SCHEMBL739526 | 0.87 | CNR1 (0.64) | CNR1CNR2ACHE | |
| SCHEMBL4425643 | 0.87 | CNR1 (0.61) | CNR1CNR2HTR2AHTR2C | |
| SCHEMBL4564027 | 0.86 | CNR1 (0.52) | CNR1CNR2ACHE | |
| SCHEMBL13574358 | 0.85 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL6358409 | 0.85 | CNR1 (0.56) | CNR1CNR2ACHE | |
| SCHEMBL6103748 | 0.84 | CNR1 (0.51) | CNR1CNR2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2111394-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2009-10-28 | — | — | EP | claimed |
| CN-101431994-A | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARM GMBH (DE) | 2009-05-13 | — | — | CN | claimed |
| CN-101431998-A | Containing CBxPharmaceutical compositions of cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARM GMBH (DE) | 2009-05-13 | — | — | CN | claimed |
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2008-09-04 | — | — | US | claimed |
| WO-2008084057-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-07-17 | — | — | WO | claimed |
| US-8138174-B2 | Such as N-{1-[7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl]heptylamino]-1-[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-methylidene)-4-chloro-benzenesulfonamide; pain. psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity; neurodegenerative disorders | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-03-20 | — | — | US | disclosed |
| US-8063062-B2 | Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficit disorder, traumatic brain injury, drug dependence, addiction; -chloro-N-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazolyl]-[7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptylamino]methylene}benzene-sulfonamide | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-11-22 | — | — | US | disclosed |
| EP-2091939-B1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2011-03-16 | — | — | EP | disclosed |
| CN-101848907-A | Has cannaboid-CB 1The compound of the combination of antagonistic action and acetylcholinesteraseinhibition inhibition | SOLVAY PHARM BV | 2010-09-29 | — | — | CN | disclosed |
| CN-101809000-A | Compounds with a combination of cannabinoid-CB1 antagonism and serotonin reuptake inhibition | SOLVAY PHARM BV | 2010-08-18 | — | — | CN | disclosed |
| EP-2111394-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2009-10-28 | — | — | EP | disclosed |
| EP-2091939-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2009-08-26 | — | — | EP | disclosed |
| EP-2026798-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-02-25 | — | — | EP | disclosed |
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2008-09-04 | — | — | US | disclosed |
| WO-2008084057-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-07-17 | — | — | WO | disclosed |
| US-20080153867-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2008-06-26 | — | — | US | disclosed |
| WO-2008074816-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007125048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
| CN-1865248-A | Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2006-11-22 | — | — | CN | disclosed |
| CN-1599724-A | Imidazole-4-carboxamide derivatives, their preparation and use in the treatment of obesity | BAYER PHARMACEUTICALS CORPORAT (US) | 2005-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153867-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION | ACHE, BACE1, BCHE | CNR1 4/4885CNR2 5/4885ACHE 1/4885 |
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | CNR1, OPRL1, CNR2 | CNR1 1/4885CNR2 3/4885ACHE 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.